Peptide specialist NeoMPS, based in Strasbourg, France has started construction of a new 2400m
2 facility that will double the company's cGMP production capacity for late stage development and commercial scale peptide manufacturing.
The company is a specialist in custom peptide synthesis and has developed many amino acid building blocks used in APIs and drug intermediates. It has 40 therapeutic products in development and a couple of those are in clinical trials.
President and ceo Serge Plaue says the company wants to handle more projects and greater volumes and it plans to take on an extra 20 people.
SNPE is a majority shareholder in the company but the investment of Euro 10m has been completely self financed. The building will be operational towards the end of 2008.
The demand for peptides is growing as more companies look to develop better targeted drugs.The company also has a catalogue of bio active peptides.